Avillion is focused on clinical co-development and financing of late-stage therapeutics. The company has formed its first deal with Pfizer and they have reported positive initial data from a global Phase III trial with Pfizer’s Bosulif™ (bosutinib) to support its approval as a first-line treatment for chronic myelogenous leukaemia.

Location London, UK
CEO Allison Jeynes-Ellis
Partner Genghis Lloyd-Harris
Website www.avillionllp.com